These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34109145)

  • 21. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
    Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
    JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
    Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
    Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.
    Bos JM; Rümke H; Welte R; Postma MJ
    Clin Ther; 2003 Oct; 25(10):2614-30. PubMed ID: 14667962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis on the project personnel's attitude and its influential factors of 23-valent pneumococcal polysaccharide vaccination program for the elderly in Shanghai].
    Guo X; Xu XX; Qiu J; Ren J; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):934-941. PubMed ID: 32907281
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population.
    Yunhua B; Peng B; Shuping L; Zheng Z
    Hum Vaccin Immunother; 2022 Nov; 18(6):2139123. PubMed ID: 36379017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.
    Caldwell R; Roberts CS; An Z; Chen CI; Wang B
    BMC Infect Dis; 2015 Jul; 15():284. PubMed ID: 26206275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Vaccine; 2019 Mar; 37(14):2026-2033. PubMed ID: 30846259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.
    Grzesiowski P; Aguiar-Ibáñez R; Kobryń A; Durand L; Puig PE
    Hum Vaccin Immunother; 2012 Oct; 8(10):1382-94. PubMed ID: 23095867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Pneumococcal Diseases Among the Elderly Aged 60 Years or Older: A Matched Test Negative Case-Control Study in Shanghai, China.
    Sun X; Guo X; Qiu J; Zhao G; Xu X; Wagner AL; Jiang H; Huang Z; Ren J; Ma X; Liang X; Yao Y; Wu J; Lu Y
    Front Public Health; 2021; 9():620531. PubMed ID: 34616702
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness analysis of pneumococcal vaccination for infants in China.
    Maurer KA; Chen HF; Wagner AL; Hegde ST; Patel T; Boulton ML; Hutton DW
    Vaccine; 2016 Dec; 34(50):6343-6349. PubMed ID: 27810315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
    Kuhlmann A; von der Schulenburg JG
    Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    J Am Geriatr Soc; 2020 Jun; 68(6):1271-1278. PubMed ID: 32086950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.
    de Soárez PC; Sartori AM; Freitas AC; Nishikawa ÁM; Novaes HM
    PLoS One; 2015; 10(6):e0130217. PubMed ID: 26114297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Won H; Kim JA; Jeong NY; Choi NK
    Vaccine; 2024 May; 42(13):3190-3196. PubMed ID: 38641496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.